top of page

PCG Molecular   Testing Menu


Detecting Cancer and Infectious Disease Before it Becomes Life-Threatening 

PCG molecular strives to change the way we practice health care. That means keeping patients healthy by screening them responsibly and regularly. Our company aspires to move patients and practitioners away from reactive care and into a proactive mindset that saves lives and improves the outcomes for many more. When our doctors and lab technicians look at developing new and innovative molecular screens we look at the following underlying principles: Will it provide the medical community and their patients with a preventive screening test that does not exist for certain cancers and diseases? Will it catch disease before it has become stage three or four cancer that is irreversible and devastating? Will it help to prevent the spread of viruses or aid in their treatment if diagnosed? Will it identify those who are at higher risk for developing a disease or a cancer so they can be watched more closely by their practitioners? And finally, is it less invasive or more effective than current test? 

Oral One PAP 

preventive oropharyngeal panel

The Oral One PAP®  is a comprehensive screening of a range of infectious diseases particularly oral infections that are transmitted sexually.


Screen Shot 2022-10-11 at 12_edited.png

Neoplastic and Oral Infectious Disease Panel


Cysto One PAP 

preventive urinary  panel 

The Cysto One PAP®  is a molecular test to screen and diagnose low and high grade urinary bladder malignancies as well as urinary tract infections and sexually transmitted diseases.


Neoplastic and GU Infectious Disease Panel

Neoplastic and Cervical Vaginal Infectious Disease Panel


Bella One PAP 

molecular cervical vaginal  panel 

The Bella One PAP®  is the first FDA-approved test to screen not only for 14 high-risk strains of HPV, but also for other sexually transmitted infections that pose a threat to women’s health.



chronic rhinosinusitis panel

The ENT One PAP®  is a comprehensive screening of chronic rhinosinusitis and chronic ottitis media infectious diseases. 


Otorhinolaryngology Infectious Disease Panel


Syndromic Testing for Joint Infections 


Joint Infection One PAP 

joint infection panel 

The Joint Infection One PAP tests for a comprehensive grouping of Gram-positive and Gram-negative bacteria, yeast, and antimicrobial resistance genes commonly associated with joint infections.


Neoplastic and Anal Infectious Disease Panel 


Anal One PAP 

molecular anorectal panel 

The Anal One PAP®  not only shows whether you have anal cancer, but also if your in a higher risk category to contract it. It’s an innovative genetic test that screens for anal cancer and its risk factors in three ways.


Respiratory Infectious Disease Panel


Respiratory One PAP 

molecular respiratory  panel 

SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. The FDA De Novo authorized PCG Molecular RP2.1 Panel® is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.


Gastrointestinal (GI) Panel

G.I One PAP 

molecular gastroenteritis panel 


The G.I One PAP® tests stool specimens for common pathogens associated with gastroenteritis. Quickly identifying the correct pathogen can ensure appropriate treatment, improve patient management, and help detect infectious gastroenteritis which can lead to severe illness or death.

bottom of page